TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
17 sept. 2021 07h30 HE
|
TCR2 Therapeutics
- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall...
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
20 juil. 2021 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with...
TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference
17 févr. 2021 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
19 janv. 2021 22h03 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies...
TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones
08 janv. 2021 08h00 HE
|
TCR2 Therapeutics
- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21 - Identification of gavo-cel recommended Phase 2 dose and initiation of Phase 2 study expected in 2021 -...
TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference
21 déc. 2020 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering...
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
13 déc. 2020 09h00 HE
|
TCR2 Therapeutics
- TC-210 induced tumor regression in all of the first eight patients - Ovarian cancer patient achieved confirmed RECIST partial response (PR) - Overall response rate (ORR) 50% in patients...
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
11 déc. 2020 16h05 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients...
TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
12 nov. 2020 06h45 HE
|
TCR2 Therapeutics
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20 - Additional clinical sites to include UCSF Medical Center and Princess Margaret Cancer Centre in the...
TCR² Therapeutics Announces Partnership with ElevateBio to Expand TC-210 Manufacturing Capacity
10 nov. 2020 08h00 HE
|
TCR2 Therapeutics
- ElevateBio BaseCamp to support anticipated TC-210 Phase 2 clinical trial demand CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...